Effects of botulinum toxin a in ambulant adults with spastic cerebral palsy: A randomized double-blind placebo-controlled trial

Journal of Rehabilitation Medicine

Volumn 43, Issue 4, 2011, Pages 338-347

  Maanum, Grethe ^a,b   Jahnsen, Reidun ^a,c   Stanghelle, Johan K ^a,b   Sandvik, Leiv ^d,e   Keller, Anne ^d  

^a SUNNAAS REHABILITATION HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

Adult; Botulinum toxin; Cerebral palsy; Gait; Muscle spasticity

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CEREBRAL PALSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GAIT; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SOCIOECONOMICS; SPASTICITY; TREATMENT OUTCOME; WALKING;

ADOLESCENT; ADULT; AGED; BOTULINUM TOXINS, TYPE A; CEREBRAL PALSY; DOUBLE-BLIND METHOD; FEMALE; GAIT; HUMANS; MALE; MIDDLE AGED; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; QUALITY OF LIFE; SELF REPORT; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; WALKING; YOUNG ADULT;

EID: 79953249308     PISSN: 16501977     EISSN: None     Source Type: Journal    
DOI: 10.2340/16501977-0672     Document Type: Article

References (42)

1. Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N, Dan B, et al. proposed definition and classification of cerebral palsy. Dev Med Child Neurol 2005; 47: 571-576. (Pubitemid 41131619)
2. Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I, Van Campenhout A, et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 2010; 14: 45-66.
3. Gage JR, Schwartz MH, Koop SE, Novacheck TF. Identification and Treatment of Gait problems in cerebral palsy. 2nd edn. clinics in developmental Medicine No. 180-181. london: Mac Keith Press; 2009.
4. Love SC, Novak I, Kentish M, desloovere K, Heinen F, Molenaers G, et al. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol 2010; 17 Suppl 2: 9-37.
5. Andersson C, Mattsson E. Adults with cerebral palsy: a survey describing problems, needs, and resources, with special emphasis on locomotion. Dev Med Child Neurol 2001; 43: 76-82. (Pubitemid 32170844)
6. Opheim A, Jahnsen R, Olsson E, Stanghelle JK. walking function, pain, and fatigue in adults with cerebral palsy: a 7-year follow-up study. Dev Med Child Neurol 2009; 51: 381-388.
7. Gracies JM. pathophysiology of spastic paresis. II: Emergence of muscle overactivity. Muscle Nerve 2005; 31: 552-571.
8. Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70: 1691-1698. (Pubitemid 351644137)
9. Olver J, Esquenazi A, Fung VS, Singer BJ, Ward AB. Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: international consensus statement. Eur J Neurol 2010; 17 Suppl 2: 57-73.
10. Caty GD, Detrembleur C, Bleyenheuft C, Deltombe T, Lejeune TM. Effect of simultaneous botulinum toxin injections into several muscles on impairment, activity, participation, and quality of life among stroke patients presenting with a stiff knee gait. Stroke 2008; 39: 2803-2808.
11. Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol 2010; 257: 1330-1337.
12. Giovannelli M, Borriello G, Castri P, Prosperini L, Pozzilli C. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil 2007; 21: 331-337. (Pubitemid 47064552)
13. Scholtes VA, Dallmeijer AJ, Knol DL, Speth LA, Maathuis CG, Jongerius PH, et al. Effect of multilevel botulinum toxin a and comprehensive rehabilitation on gait in cerebral palsy. Pediatr Neurol 2007; 36: 30-39. (Pubitemid 46427789)
14. Jeglinsky I, Surakka J, Carlberg EB, Autti-Ramo I. Evidence on physiotherapeutic interventions for adults with cerebral palsy is sparse. A systematic review. Clin Rehabil 2010; 24: 771-788.
15. Richardson D, Sheean G, werring D, Desai M, Edwards S, Greenwood R, et al. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry 2000; 69: 499-506.
16. Bergfeldt U, Borg K, Kullander K, Julin P. focal spasticity therapy with botulinum toxin: effects on function, activities of daily living and pain in 100 adult patients. J Rehabil Med 2006; 38: 166-171. (Pubitemid 43731149)
17. Bergfeldt U, Skold C, Julin P. Short form 36 assessed healthrelated quality of life after focal spasticity therapy. J Rehabil Med 2009; 41: 279-281.
18. Gracies JM, Lugassy M, Weisz DJ, Vecchio M, Flanagan S, Simpson DM. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehabil 2009; 90: 9-16.
19. world Health organization. International classification of functioning, disability and Health. Geneva: world Health organization; 2001.
20. Cans C. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Surveillance of Cerebral Palsy in Europe (SCPE). Dev Med Child Neurol 2000; 42: 816-824. (Pubitemid 32010983)
21. Ghotbi N, Ansari NN, Naghdi S, Hasson S, Jamshidpour B, Amiri S. Inter-rater reliability of the Modified Modified Ashworth Scale in assessing lower limb muscle spasticity. Brain Inj 2009; 23: 815-819.
22. Maanum G, Jahnsen R, Froslie KF, Larsen KL, Keller A. walking ability and predictors of performance on the 6-minute walk test in adults with spastic cerebral palsy. Dev Med Child Neurol 2010; 52: e126-132.
23. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997; 39: 214-223. (Pubitemid 27226331)
24. Desloovere K, Molenaers G, Jonkers I, De CJ, De BL, Nijs J, et al. A randomized study of combined botulinum toxin type A and casting in the ambulant child with cerebral palsy using objective outcome measures. Eur J Neurol 2001; 8 Suppl 5: 75-87. (Pubitemid 33757693)
25. O'Brien CF. Injection Techniques for botulinum toxin using electromyography and electrical stimulation. In; Spasticity;aetiology, evaluation, management and the role of botulinum toxin. New york: we Move, 2002: 131-133.
26. Mayer NH, Simpson DM. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset muscle over activity in patients with an upper motor neuron lesion. In; Mayer NH, Simpson DM, ed. Spasticity; aetiology, evaluation, management and the role of botulinum toxin. New york: we Move; 2002, p. 154-165.
27. Caspersen CJ, Powell KE, Christenson GM. physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public Health Rep 1985; 100: 126-131. (Pubitemid 15064369)
28. Loge JH, Kaasa S, Hjermstad MJ, Kvien TK. Translation and performance of the Norwegian SF-36 Health Survey in patients with rheumatoid arthritis. I. Data quality, scaling, assumptions, reliability, and construct validity. J Clin Epidemiol 1998; 51: 1069-1076. (Pubitemid 28527162)
29. Ware J. Sf-36 Health Survey Manual and Interpretation Guide. 2nd edn. Boston: The Health Institute; New England Medical Centre; 1997.
30. Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 2010; 70: 121-145.
31. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and diseasespecific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43: 1478-1487. (Pubitemid 30452465)
32. Podsiadlo D, Richardson S. The timed "up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991; 39: 142-148.
33. Nilsagard Y, Lundholm C, Gunnarsson LG, Denison E. clinical relevance using timed walk tests and 'timed up and go' testing in persons with multiple sclerosis. Physiother Res Int 2007; 12: 105-114.
34. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
35. Andersson C, Asztalos L, Mattsson E. Six-minute walk test in adults with cerebral palsy. A study of reliability. Clin Rehabil 2006; 20: 488-495. (Pubitemid 44102821)
36. Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008; 30: 974-985. (Pubitemid 351799873)
37. Fagerland MW, Sandvik L. performance of five two-sample location tests for skewed distributions with unequal variances. Contemp Clin Trials 2009; 30: 490-496.
38. Bjornson K, Hays R, Graubert C, Price R, Won F, Mclaughlin JF, et al. Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation. Pediatrics 2007; 120: 49-58. (Pubitemid 47036240)
39. Robertson JV, Pradon D, Bensmail D, Fermanian C, Bussel B, Roche N. Relevance of botulinum toxin injection and nerve block of rectus femoris to kinematic and functional parameters of stiff knee gait in hemiplegic adults. Gait posture 2009; 29: 108-112.
40. Frost FA, Jessen B, Siggaard-Andersen J. A control, double-blind comparison of mepivacaine injection versus saline injection for myofascial pain. lancet 1980; 1: 499-500. (Pubitemid 10176619)
41. Rawicki B, Sheean G, Fung VS, Goldsmith S, Morgan C, Novak I. Botulinum toxin assessment, intervention and aftercare for paediatric and adult niche indications including pain: international consensus statement. Eur J Neurol 2010; 17 Suppl 2: 122-134.
42. Hays RD, Hahn H, Marshall G. use of the Sf-36 and other health-related quality of life measures to assess persons with disabilities. Arch Phys Med Rehabil 2002; 83: S4-S9. (Pubitemid 35424683)